Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report

BACKGROUND: Unprecedented durable responses are identified in clinical studies to target the signaling of programmed cell death protein-1 (PD-1) as well as its ligand (PD-L1) in patients with squamous-cell non-small cell lung cancer (NSCLC). However, factors predicting the patient subtypes that are...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Cheng, Zhang, Chu, Zhao, Wei-Qing, Hu, Wen-Wei, Wu, Jun, Ji, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794845/
https://www.ncbi.nlm.nih.gov/pubmed/31619231
http://dx.doi.org/10.1186/s12920-019-0592-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794845/
https://www.ncbi.nlm.nih.gov/pubmed/31619231
http://dx.doi.org/10.1186/s12920-019-0592-6

Ejemplares similares